In the 2017 ACC/AHA guidelines for risk stratification in patients with chronic heart failure, novel markers of myocardial remodeling [soluble suppression of tumorigenesis 2 (sST2) and galectin-3 (Gal-3)] were given a class IIb recommendation for use in clinical practice (51). Here, LGALS3 is linked to congestive heart failure.